Vandetanib Stalls Progression of Metastatic Medullary Thyroid Cancer, Stanford University Study
CHICAGO (EGMN) – Vandetanib, a multitargeted experimental agent, significantly delayed progression of locally advanced or metastatic medullary thyroid cancer in a randomized, placebo-controlled, phase III trial.